Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development

具有肿瘤学和免疫肿瘤学专业知识的行业资深人士，以及通过临床开发推进项目的良好记录

PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ('Carisma' or the 'Company'), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer.

费城，2024年5月2日/PRNewswire/--Carisma Therapeutics Inc。（纳斯达克：CARM）（“Carisma”或“公司”）是一家专注于发现和开发创新免疫疗法的临床阶段生物制药公司，今天宣布任命Eugene P.Kennedy，M.D.，F.a.C.S.为公司首席医疗官。

Dr. Kennedy brings over 15 years of clinical and industry experience, including cross-functional leadership driving clinical development and regulatory strategies for oncology and immuno-oncology focused organizations. In the role of Chief Medical Officer, Dr. Kennedy will be responsible for overseeing Carisma's clinical development, regulatory and medical affairs functions..

肯尼迪博士拥有超过15年的临床和行业经验，包括跨职能领导，推动肿瘤学和免疫肿瘤学重点组织的临床开发和监管策略。作为首席医疗官，肯尼迪博士将负责监督Carisma的临床开发、监管和医疗事务职能。。

'On behalf of Carisma, I am delighted to welcome Gene to our team,' said Steven Kelly, President and Chief Executive Officer of Carisma. 'With his extensive expertise in oncology and a proven track record in designing and executing clinical trials for solid tumors, Dr. Kennedy brings invaluable insights to our organization that should immediately have a positive impact.

Carisma总裁兼首席执行官史蒂文·凯利（StevenKelly）说，我很高兴代表Carisma欢迎吉恩加入我们的团队凭借他在肿瘤学方面的丰富专业知识以及在设计和执行实体瘤临床试验方面的良好记录，肯尼迪博士为我们的组织带来了宝贵的见解，应该会立即产生积极的影响。

We are excited to add his leadership to our organization to build on the momentum in our clinical program and to help advance our pipeline to deliver innovative treatments to patients.'.

我们很高兴能将他的领导加入到我们的组织中，以巩固我们临床计划的势头，并帮助推进我们为患者提供创新治疗的渠道。”。

'I am excited to join Carisma, a company at the forefront of developing engineered macrophages across various therapeutic areas,' said Dr. Kennedy. 'It is an exciting time for Carisma as it progresses its anti-HER2 program through clinical development. Throughout my career, I have always been driven to seek out new modalities with the potential to profoundly impact patients' lives, and Carisma represents an extraordinary opportunity for me to fulfill this mission.'.

肯尼迪博士说：“我很高兴加入Carisma，这是一家在各个治疗领域开发工程巨噬细胞的前沿公司。”对于Carisma来说，这是一个激动人心的时刻，因为它通过临床开发推进了抗HER2计划。在我的职业生涯中，我一直在寻求新的方式，这些方式有可能深刻影响患者的生活，而Carisma为我完成这一使命提供了一个非凡的机会。”。

Before joining Carisma, Dr. Kennedy served as Chief Medical Officer at Galera Therapeutics, where he oversaw the development of the company's radiotherapy in cancer. Prior to his time at Galera, Dr. Kennedy served as Chief Medical Officer at Innovative Cellular Therapeutics, where he played a pivotal role in developing the Phase 1 clinical protocol and securing a first-in-human IND for a solid tumor CAR T-cell therapy.

在加入Carisma之前，Kennedy博士曾担任Galera Therapeutics的首席医疗官，负责监督该公司癌症放射治疗的发展。在Galera任职之前，Kennedy博士曾担任Innovative Cellular Therapeutics的首席医疗官，他在开发第一阶段临床方案和确保实体瘤CAR T细胞治疗的首次人类IND方面发挥了关键作用。

Previously, he served as Chief Medical Officer at Lumos Pharma, where he was responsible for clinical development strategy and execution, alongside investor and patient engagement efforts. Before Lumos, Dr. Kennedy held the role of Chief Medical Officer at NewLink Genetics, overseeing clinical trials across multiple product candidates and indications.

此前，他曾担任Lumos Pharma的首席医疗官，负责临床开发战略和执行，以及投资者和患者的参与工作。在Lumos之前，Kennedy博士担任NewLink Genetics的首席医疗官，负责监督多种候选产品和适应症的临床试验。

Prior to joining NewLink Genetics, he served as Associate Professor of Surgery at Thomas Jefferson University and held leadership positions as Chief of the Section of Pancreatic and Hepatobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary & Related Cancers Center. Dr. Kennedy also has practiced, taught, and held leadership roles at the Johns Hopkins Hospital and Louisiana State University.

在加入NewLink Genetics之前，他曾担任托马斯·杰斐逊大学外科副教授，担任胰腺和肝胆外科主任以及杰斐逊胰腺，胆道和相关癌症中心联合主任。肯尼迪博士还在约翰·霍普金斯医院和路易斯安那州立大学实习、教学并担任领导职务。

Dr. Kennedy received a bachelor's degree from the University of Virginia and an M.D. from the Medical College of Virginia..

肯尼迪博士获得弗吉尼亚大学学士学位和弗吉尼亚医学院医学博士学位。。

About Carisma

关于Carisma

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response.

Carisma Therapeutics Inc.是一家临床阶段的生物制药公司，专注于利用我们专有的巨噬细胞和单核细胞工程平台开发用于治疗癌症和其他严重疾病的转化性免疫疗法。我们已经创建了一个全面的，分化的专有细胞治疗平台，专注于工程化巨噬细胞和单核细胞，这些细胞在先天性和适应性免疫反应中起着至关重要的作用。

Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com..

Carisma总部位于宾夕法尼亚州费城。有关更多信息，请访问www.carismatx.com。。

Investors:

投资者：

Shveta Dighe

Shveta Dighe

Head of Investor Relations

投资者关系主管

investors@carismatx.com

investors@carismatx.com

Media Contact:

媒体联系人：

Julia Stern

朱莉娅·斯特恩

(763) 350-5223

(763) 350-5223

jstern@realchemistry.com

jstern@realchemistry.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-appoints-dr-eugene-p-kennedy-as-chief-medical-officer-302133840.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/carisma-therapeutics-appoints-dr-eugene-p-kennedy-as-chief-medical-officer-302133840.html

SOURCE Carisma Therapeutics Inc.

来源Carisma Therapeutics Inc。

Company Codes: NASDAQ-NMS:CARM

公司代码：NASDAQ-NMS：CARM